Janux Therapeutics (JANX) Competitors $48.76 -2.34 (-4.58%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends JANX vs. SRRK, DICE, PAND, PRAX, IGMS, SRPT, QGEN, RVMD, ITCI, and ROIVShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Scholar Rock (SRRK), DICE Therapeutics (DICE), Pandion Therapeutics (PAND), Praxis Precision Medicines (PRAX), IGM Biosciences (IGMS), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Revolution Medicines (RVMD), Intra-Cellular Therapies (ITCI), and Roivant Sciences (ROIV). These companies are all part of the "medical" sector. Janux Therapeutics vs. Scholar Rock DICE Therapeutics Pandion Therapeutics Praxis Precision Medicines IGM Biosciences Sarepta Therapeutics Qiagen Revolution Medicines Intra-Cellular Therapies Roivant Sciences Scholar Rock (NASDAQ:SRRK) and Janux Therapeutics (NASDAQ:JANX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk. Does the media prefer SRRK or JANX? In the previous week, Scholar Rock had 15 more articles in the media than Janux Therapeutics. MarketBeat recorded 28 mentions for Scholar Rock and 13 mentions for Janux Therapeutics. Scholar Rock's average media sentiment score of 0.41 beat Janux Therapeutics' score of -0.33 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer SRRK or JANX? Scholar Rock received 130 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Janux Therapeutics an outperform vote while only 65.32% of users gave Scholar Rock an outperform vote. CompanyUnderperformOutperformScholar RockOutperform Votes16265.32% Underperform Votes8634.68% Janux TherapeuticsOutperform Votes3266.67% Underperform Votes1633.33% Which has preferable valuation & earnings, SRRK or JANX? Janux Therapeutics has lower revenue, but higher earnings than Scholar Rock. Janux Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M74.71-$165.79M-$2.35-11.27Janux Therapeutics$13.05M196.11-$58.29M-$1.17-41.68 Which has more risk and volatility, SRRK or JANX? Scholar Rock has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.52, suggesting that its stock price is 252% more volatile than the S&P 500. Is SRRK or JANX more profitable? Scholar Rock has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -145.60% -91.83% Janux Therapeutics -463.91%-10.47%-9.86% Do analysts rate SRRK or JANX? Scholar Rock currently has a consensus target price of $34.00, indicating a potential upside of 28.35%. Janux Therapeutics has a consensus target price of $66.44, indicating a potential upside of 36.27%. Given Janux Therapeutics' higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Do insiders & institutionals believe in SRRK or JANX? 91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 19.2% of Scholar Rock shares are held by insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryJanux Therapeutics beats Scholar Rock on 10 of the 19 factors compared between the two stocks. Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.56B$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-41.6710.1698.9217.12Price / Sales196.11266.571,205.7371.29Price / CashN/A53.4940.6936.36Price / Book3.909.306.325.87Net Income-$58.29M$154.14M$119.47M$225.66M7 Day Performance-9.57%-9.49%-5.11%-1.34%1 Month Performance-1.32%-7.23%-3.21%1.00%1 Year Performance452.83%30.70%32.41%25.27% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics3.593 of 5 stars$48.76-4.6%$66.44+36.3%+452.8%$2.56B$8.08M-41.6730Analyst ForecastSRRKScholar Rock4.6067 of 5 stars$26.49-3.7%$34.00+28.4%+125.3%$2.48B$33.19M-11.27140Analyst ForecastAnalyst RevisionNews CoverageDICEDICE TherapeuticsN/A$47.55flatN/AN/A$2.27B$1.13M-20.3271PANDPandion TherapeuticsN/A$60.05flatN/AN/A$1.77B$970,000.000.0056PRAXPraxis Precision Medicines1.7896 of 5 stars$71.76-6.7%$146.33+103.9%+398.0%$1.34B$2.45M-6.97110Insider SellingNews CoverageIGMSIGM Biosciences4.6905 of 5 stars$9.47-6.2%$16.13+70.3%+64.4%$561.75M$2.13M-2.60190Earnings ReportShort Interest ↓SRPTSarepta Therapeutics4.9455 of 5 stars$104.54-4.2%$181.33+73.5%+26.0%$9.99B$1.64B83.631,314Analyst UpgradeQGENQiagen4.2892 of 5 stars$41.27-1.9%$50.88+23.3%+1.6%$9.42B$1.97B105.825,967Analyst RevisionRVMDRevolution Medicines3.5596 of 5 stars$55.13-3.9%$61.00+10.6%+159.4%$9.27B$11.58M-15.36443ITCIIntra-Cellular Therapies4.5093 of 5 stars$83.42-4.8%$97.23+16.6%+51.6%$8.84B$464.37M-95.88560Insider SellingPositive NewsROIVRoivant Sciences3.4226 of 5 stars$11.20-3.8%$17.93+60.1%+24.2%$8.28B$124.79M1.98860Analyst ForecastNews CoverageHigh Trading Volume Related Companies and Tools Related Companies SRRK Competitors DICE Competitors PAND Competitors PRAX Competitors IGMS Competitors SRPT Competitors QGEN Competitors RVMD Competitors ITCI Competitors ROIV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JANX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JANX Stock Alerts